We previously showed that inhibition of protein kinase C delta (PKCd) improves brain perfusion 24 hours after asphyxial cardiac arrest (ACA) and confers neuroprotection in the cortex and CA1 region of the hippocampus 7 days after arrest. Therefore, in this study, we investigate the mechanism of action of PKCd-mediated hypoperfusion after ACA in the rat by using the two-photon laser scanning microscopy (TPLSM) to observe cortical cerebral blood flow (CBF) and laser Doppler flowmetry (LDF) detecting regional CBF in the presence/absence of dV1-1 (specific PKCd inhibitor), nitric oxide synthase (NOS) substrate (L-arginine, L-arg) and inhibitor (N o -Nitro-L-arginine, NLA), and nitric oxide (NO) donor (sodium nitroprusside, SNP). There was an increase in regional LDF and local (TPLSM) CBF in the presence of dV1-1 þ L-arg, but only an increase in regional CBF under dV1-1 þ SNP treatments. Systemic blood nitrite levels were measured 15 minutes and 24 hours after ACA. Nitrite levels were enhanced by pretreatment with dV1-1 30 minutes before ACA possibly attributable to enhanced endothelial NOS protein levels. Our results suggest that PKCd can modulate NO machinery in cerebral vasculature. Protein kinase C delta can depress endothelial NOS blunting CBF resulting in hypoperfusion, but can be reversed with dV1-1 improving brain perfusion, thus providing subsequent neuroprotection after ACA.
INTRODUCTION
We previously showed that inhibition of protein kinase C delta (PKCd) via dV1-1 can increase perfusion 24 hours after asphyxial cardiac arrest (ACA). Global cerebral ischemia (via ACA) causes derangement of cerebral blood flow (CBF) responsible for neuronal cell death in the CA1 region of the hippocampus as well as the cortex. 1 Owing to the overall decrease in CBF after ischemia, neuronal cell death 1 can occur in major regions of the brain responsible for learning, memory, and cognitive function. 2 It is thought that during global ischemia, PKCd (a novel PKC) levels are elevated causing PKCd to translocate to the nucleus (activation) resulting in cellular damage. In the normal brain, PKCd levels are nominal whereas global ischemia can cause activation/translocation of PKCd. 3 Inhibition of PKCd (via specific inhibitor of PKCd, dV1-1) can cause a revival of CBF 24 hours after ischemia to counteract hypoperfusion or low CBF found to be suppressed after cardiac arrest from 38% to 65%. 1, 4 We previously showed that pretreatment of dV1-1 before ACA can enhance perfusion 24 hours after ischemia, resulting in improved neuronal survival in the hippocampal CA1 and cortex regions in our rat model of ACA. 1 Here, we sought out to define the specific mechanism(s) of how inhibition of PKCd can alleviate these pathologies. The possible endothelium and endothelial-mediated nitric oxide synthase (eNOS) involvement as a target for PKCd relating to general circulation was first reported by Monti et al. 5 This led to these current experiments in the brain by utilizing inhibitors and substrates related to nitric oxide synthase (NOS). Our results suggest that pretreatment with dV1-1 before ACA can activate eNOS machinery suggesting that the enhancement of perfusion may be attributed to enhanced CBF. This is further supported by the fact that L-arg (a substrate for nitric oxide (NO) production) and sodium nitroprusside (SNP, NO donor) can both enhance CBF in the nonischemic rat as measured by two-photon laser scanning microscopy (TPLSM) of cortical microvessels as well as laser Doppler flowmetry (LDF, a measure of regional CBF). Systemic whole-blood nitrite (NO metabolite) was also measured before and after ACA in the presence or absence of dV1-1. Administration of dV1-1 mediated increased perfusion, enhanced nitrite levels 24 hours after ACA as compared with control suggesting the involvement of NO modulation. In addition, only eNOS levels (as opposed to other evaluated NOS isoforms) were elevated during this process. Here, we show that inhibition of PKCd before ACA can alleviate the detrimental effects of hypoperfusion via eNOS activation. diluted in sterile saline and injected (700 mL total injection volume) into the Sprague-Dawley rat intravenously. Protein kinase C delta inhibitor (dV1-1) and tat carrier peptide (0.5 mg/kg) (KAI pharmaceuticals, San Francisco, CA, USA) were dissolved in sterile saline (0.9%) and injected into the rat intravenously (700 mL total injection volume). Each drug was administered every 30 minutes as denoted in Figures 1A and 2A.
Animal Preparation
All procedures were approved by the Institutional Animal Care and Use Committee (University of Miami, Miller School of Medicine) and written up in accordance with ARRIVE. Adult male Sprague-Dawley rats (250 to 350 g) were fasted overnight before surgery. Rats were anesthetized with 4% isoflurane and 30:70 mixture of O 2 and N 2 O, followed by endotracheal intubation. Isoflurane was lowered to 1.5% to 2% for endovascular access. The femoral vein and artery were cannulated using a single-lumen (PE-50) catheter for blood pressure monitoring, blood gas analysis, and intravenous injection of pharmacological agents. The rats were immobilized with vecuronium bromide (2.0 mg/kg, intravenously, administered every 10 minutes) and maintained immobilized throughout the procedure. Head and body temperatures were maintained at 371C using heating blankets and lamps.
Thinned-Skull Window Method
The thinned-skull window method is a modified method from Xu et al. 6 Anesthetized rats were placed on a stereotaxic frame to ensure the stability of the rat. After femoral arteries and vein of the rat were cannulated and carotid ligatures installed, a longitudinal incision extending from the neck region to the frontal area of the rat was made at the midline scalp using microsurgical tools. Utilizing a high-speed microdrill, a thin circular area of the skull (B2 mm in diameter) was made 1 mm lateral to the bregma. Thinned-skull window was created carefully with a microdrill thinning out the skull with constant irrigation with sterile saline so as to not overheat the skull or the drill bit. The skull is thin enough for visualization of blood vessels via TPLSM when it is approximately half the thickness of the skull or approximately 0.5 mm. 1, 6 Two-photon Laser Scanning Microscopy After thinning the skull, the rat was placed on a TPLSM (Lasersharp2000, Bio-Rad, Hercules, CA, USA). pH, mean arterial blood pressure, pCO 2 , pO 2 , glucose, rectal, and head temperatures were constantly monitored throughout the experiment. A 20 Â water immersion objective (Olympus XLUMPlanFl) was lowered in proximity to the thinned-skull window. Fluorescent images were captured (every 5 to 15 minutes) at an excitation wavelength of 910 nm with the intravenous introduction of low molecular weight fluorescein-dextran. Cortical cerebral blood vessel images were captured at 20 Â and 200 Â. Additionally, Z-series (20 Â ) and linescan (200 Â ) images were obtained throughout the time course of the experiment starting with t ¼ 0 (before the introduction of drugs). We have previously experienced no immediate change in physiologic variables or change in CBF or blood vessel diameters upon acute administration of tat peptide or dV1-1. 1 Only microvessels with diameters 5 to 10 mm were TPLSM measurements in normal rats Figure 1 . Schematic diagram of the experimental design. (A) Baseline two-photon laser scanning microscopy (TPLSM) measurements were acquired before any drug administration. Subsequently, L-arg (100 mg/kg) or sodium nitroprusside (SNP) (0.75 mg/kg) was injected (bolus, intravenously) into the rat. After drug injection, a linescan image was acquired via TPLSM at 5, 10, 15, and 30-minute intervals (represented with gray arrows). After administration of SNP, dV1-1 (0.5 mg/kg) was injected with a subsequent dose of L-arg (100 mg/kg) or SNP (0.75 mg/kg) administered intravenously 30 minutes after the introduction of dV1-1. Linescan image acquisition via TPLSM was implemented at 5, 10, 15, and 30-minute intervals. (B) Inhibition of protein kinase C delta (PKCd) promoted L-arg-induced enhancement of cortical cerebral blood flow (CBF) via TPLSM. We used TPLSM to examine local CBF within the cortical microvessels (penetrating pial microvessels). Administration of L-arg (100 mg/kg) or SNP (0.75 mg/kg) alone did not produce a profound change in CBF. However, upon administration of dV1-1 (for 30 minutes), Larg (216 ± 48%, at t ¼ 105 minutes) but not SNP-enhanced CBF (n ¼ 9, *Pp0.05). considered for TPLSM studies. Upon visual inspection, arterioles can be recognized morphologically based on arterioles branching out from larger vessels, while, venules merge into larger vessels. 7 Linescans for red blood cell (RBC) velocity measurements were analyzed with ImageJ analysis software. 8 Each velocity measurement was calculated by measuring the slope of the dark lines (10 lines) representing 10 RBCs traversing at a point in time of the linescan. The slopes were calculated and averaged. One microvessel was studied per rat with an overall diameter on average of 10 mm. Linescan images were captured and measured as denoted in Figure 1A as 'TPLSM measurements in normal rats'. Our data were expressed as percent change in flow. This was achieved by utilizing each rat as its own internal control. Baseline measurements before drug treatment were used for normalization of the data. This analysis was necessary owing to the fact that not all microvasculature possess exactly the same vessel size or RBC velocities before ischemia and drug treatments. Statistical analysis was evaluated by one-way ANOVA followed by Tukey's post hoc test.
Laser Doppler Flowmetry
Laser doppler flowmetry measurements were obtained to determine CBF dynamics of cortical blood vessels in rats with no treatment (baseline), tat peptide or dV1-1 (0.5 mg/kg), L-arg (100 mg/kg), NLA (10 mg/kg), and SNP (0.75 mg/kg) (all bolus with 700 mL total injection volume at 30 minute intervals, intravenously). Laser Doppler flowmetry measurements of blood perfusion were monitored at the start of the experiment and continuously recorded (2 Hz sampling frequency) (30 minutes for each drug injection) until the end of the final drug injections. To monitor blood perfusion in the cerebral cortex, a 2 mm 2 burr hole was made over the left frontoparietal cortex B1 mm lateral to the bregma. The bone was drilled to a thin layer with a cutting burr under saline irrigation, and a cortical area with blood vessels less than 50 mm diameter was selected by visualization through the thin bone layer, and a fiber optic probe (1 mm 2 ) was placed thereupon. The fiber optic probe, when coupled to a PeriFlux 4001 Master laser Doppler blood perfusion monitor (Perimed, Jarfalla, Sweden), measures cerebral blood perfusion in a 1 mm 3 tissue region. The Doppler signals were routed to a polygraphic recording system interfaced to a personal computer, via an A to D converter, utilizing data acquisition software (Perisoft for Windows, Jarfalla, Sweden). The average of all peak values of each 30minute drug treatment was averaged and calculated using the 2 Hz sampling rate. All data are expressed as mean±s.e.m. 9 Statistical analysis was evaluated by one-way ANOVA followed by Tukey's post hoc test.
Asphyxial Cardiac Arrest
To induce ACA, apnea was induced by disconnecting the ventilator from the endotracheal tube. Six minutes after asphyxia, resuscitation was initiated by administering a bolus injection of epinephrine (0.005 mg/kg, intravenously) and sodium bicarbonate (1 mEq/kg, intravenously) followed by mechanical ventilation. Arterial blood gases were measured before and . Laser Doppler flowmetry measurement of regional cerebral blood flow (CBF) was recorded for 30 minutes before the start of each experiment to obtain baseline measurements (t ¼ 0 to 30 minutes). Subsequently tat peptide or dV1-1 (0.5 mg/kg) was administered and regional CBF was recorded for 30 minutes. Subsequent bolus injections of L-arg (100 mg/kg), N o -Nitro-Larginine (NLA) (10 mg/kg), and sodium nitroprusside (SNP) (0.75 mg/kg) were introduced every 30 minutes with continuous LDF recordings at 2 Hz. (B) Inhibition of protein kinase C delta (PKCd) promoted L-arg and SNP-induced enhancement of regional CBF via LDF. We used LDF to examine regional CBF. Administration of L-arg (100 mg/kg) (121±5%), NLA (10 mg/kg) (110±4%), or SNP (0.75 mg/kg) (143±8%) in the presence of tat peptide (n ¼ 7) did not produce profound changes in CBF. However, upon administration of dV1-1 (for 30 minutes, n ¼ 8), L-arg (155 ± 13%) and SNP (188 ± 11%) enhanced CBF (n ¼ 7 to 8, *Pp0.05).
Continuous LDF measurements (2 Hz) in normal rats
after ACA. Control animals (sham) were subjected to surgical procedures similar to ACA animals except without induction of ACA. Resuscitation drugs were not used; however, sham animals were treated with isoflurane similar to experimental animals. Based on our prior experiences, administration of epinephrine in sham animals does not have any CBF differences after the blood pressure returns to normal. The rats were immobilized with vecuronium bromide (2.0 mg/kg, intravenously, administered every 10 minutes) and maintained immobilized throughout the procedure. 1 
Whole-Blood Nitrite Analysis
Rat whole-blood was extracted before, 15 minutes, and 24 hours after ACA. Nitrite preservation solution was added to the whole blood. Nitrite measurements were determined by tri-iodide-based gas-phase reductive chemiluminescence with an NO analyzer (GE Analytic, Boulder, CO, USA) as described previously. 10 Nitrite concentrations were calculated based on the area under the curve (peak) utilizing a known reference injection of nitrite. Statistical analysis was evaluated by one-way ANOVA followed by Tukey's post hoc test.
Western Blot Analysis
Rats were prepared as noted in the 'animal preparation' section. Rats were injected with either tat peptide or dV1-1 and 6 minutes of ACA was performed as already mentioned. One hour after tat peptide or dV1-1 injection with or without ACA, the rats were killed and the brain excised. The cortex (the region of CBF measurements via LDF and TPLSM) was extracted and homogenized using a glass homogenizer in RIPA (50 mmol/L Tris pH 8, 150 mmol/L NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, and 1% SDS). The homogenate was centrifuged at 13,000 Â g for 15 minutes at 41C and the protein fractions were quantified using the Bradford Assay (Bio-Rad Dc Protein Assay, Hercules, CA, USA). Equal amounts of protein (50 mg) were separated on a 10% SDS-PAGE gel and electroblotted to nitrocellulose. Membranes were blocked with 5% bovine serum albumin/tris buffered saline with tween 20 (TBS-T) (for phosphospecific antibodies) or 5% milk/TBS-T (non-phospho-specific antibodies) then incubated in primary antibody at 41C overnight. Primary antibodies were obtained from Cell Signaling (Boston, MA, USA; phospho-eNOS (Ser1177), nNOS) and Abcam (Cambridge, MA, USA; eNOS, iNOS). Proteins were detected by appropriate horseradish peroxidase-conjugated secondary antibodies (GE Healthcare UK Limited, Buckinghamshire, UK) and enhanced chemiluminescence (ECL) system (Pierce Thermo Scientific, Rockford, IL, USA). Protein loading was determined by re-probing the membrane for b-actin (Sigma-Aldrich). The blots were imaged and analyzed using Bio-Rad Quantity One Analysis Software. Graphical results are expressed as fold change from tat peptide normalized to b-actin. Statistical analysis was evaluated by one-way ANOVA followed by Tukey's post hoc test or Student's t-test for unpaired samples as appropriate with SPSS statistical software (Chicago, IL, USA).
Statistical Analysis
Results were expressed as means ± s.e.m. Statistical analysis was evaluated by one-way ANOVA followed by Tukey's post hoc test or Student's t-test for paired or unpaired samples as appropriate with SPSS statistical software. The Pp0.05 level of probability was accepted as significant.
RESULTS

Protein Kinase C Delta Modulates L-Arginine-induced Enhancement of Cerebral Blood Flow in Cortical Microvessels
We previously showed that inhibition of PKCd via dV1-1 can cause an increase in CBF 24 hours after ACA blunting hypoperfusion. 1 This leads to our current hypothesis that PKCd alone can modulate NO machinery in acute or chronic situations. We applied (see Figure 1A , experimental paradigm) L-arg (100 mg/kg) (substrate for NOS) or SNP (0.75 mg/kg) (NO donor) to determine if NO is involved in PKCd-mediated CBF via TPLSM of cortical microvessels. Rats injected (bolus) with L-arg or SNP for 30 minutes each did not produce any overall significant increases in cortical CBF. It is important to note that upon time (t) ¼ 5 to 15 minutes of L-arg perfusion, cortical CBF was enhanced indicating the efficacy of L-arg in promoting enhanced CBF. In addition, infusion of SNP after L-arg at t ¼ 35 to 45 minutes produced a small enhancement of CBF suggestive of the actions of the NO donor. 11 Furthermore, rats injected with dV1-1 (30 minutes) and then L-arg (30 minutes) resulted in enhanced peak cortical CBF (216±48%, at t ¼ 105 minutes) as compared with L-arg alone (113±11%, at t ¼ 5 minutes) (n ¼ 9) ( Figure 1B) . Administration of SNP after dV1-1 did not produce any significant changes in CBF. These results indicate that inhibition of PKCd can enhance L-arg-induced enhancement of CBF suggesting that PKCd can modulate NO in the cortical microvessels. It is also important to note that the concentrations of L-arg, NLA, and SNP, were selected by administering the drugs at a high enough dose without acute or chronic side effects (i.e. drastic lowering of systemic blood pressure). In addition, the infusion concentrations of L-arg, [12] [13] [14] NLA, [15] [16] [17] and SNP 18, 19 were readily used by other investigators.
Protein Kinase C Delta Modulates L-arginine and Sodium Nitroprusside-induced Enhancement of Regional Cerebral Blood Flow The usage of TPLSM to observe cortical microvessels gives a focal perspective on cortical CBF at a point in time; therefore, we also used LDF to obtain a regional perspective on CBF at a high data sampling rate of 2 Hz as opposed to TPLSM (every 5 to 15 minutes after induction of drugs) ( Figure 2 ). The LDF probe was placed in the same position as the TPLSM objective of 1 mm lateral to the bregma. Our LDF results suggest that the introduction of dV1-1 with subsequent L-arg (100 mg/kg) administration enhanced regional CBF (155±13%) as compared with tat peptide þ L-arg (121 ± 5%). No significant difference in regional CBF was observed with the administration of dV1-1 þ NLA (124±8%) as compared with tat peptide þ NLA (110±4%). Contrary to the TPLSM study, administration of dV1-1 þ SNP (188 ± 11%) enhanced regional CBF as compared with tat peptide þ SNP (143 ± 8%) (n ¼ 7 to 8) ( Figure 2B ).
Whole-blood Nitrite Concentration is Enhanced via Inhibition of Protein Kinase C Delta After Cardiac Arrest
In order to determine the possible mechanism of action of PKCdmediated enhancement of CBF, we measured nitrite concentration in systemic whole-blood 15 minutes and 24 hours after ACA with tat peptide or dV1-1 pretreated for 30 minutes before the induction of ACA. Animals pretreated with dV1-1 presented with an enhanced nitrite concentration in systemic whole blood (2.50±0.61 mmol/L) 24 hours after ACA as compared with Sham, ACA only, or tat peptide (vehicle) þ ACA (Figure 3 ). Physiologic parameters are provided in Table 1 . PO 2 for all groups (after ACA) were greater than 150 mm Hg owing to 100% delivery of oxygen and increased ventilator rate (60 to 80 breaths per minute) during and after resuscitation. As nitrite is a metabolite of NO, 20 it is suggestive that NO was the mostly likely cause of the enhanced CBF 24 hours after ACA as previously shown 1 with TPLSM.
Endothelial Nitric Oxide Synthase is Enhanced via Inhibition of Protein Kinase C Delta After Cardiac Arrest
As nitrite concentrations were enhanced in the presence of PKCd inhibitor (via dV1-1), we performed protein analyses via Western blot for eNOS, phosphorylated-eNOS (P-eNOS), inducible NOS (iNOS), and neuronal NOS (nNOS) in the presence of tat peptide or dV1-1 (administered 30 minutes before ACA). Cortex samples (to undergo Western blot analyses, 1 mm lateral to the bregma) were isolated after the animal was killed 24 hours after ACA. Endothelial-mediated nitric oxide synthase but not P-eNOS ( Figure 4A ), iNOS ( Figures 4C and 4D ), or nNOS ( Figures 4E and 4F) was enhanced in the presence of dV1-1 þ ACA (1.29±0.12%) as compared with tat peptide þ ACA (1.00±0.08%) or dV1-1 only (0.95 ± 0.01%) (without ACA) ( Figure 4B ). Physiologic parameters are provided in Table 2 . PO 2 for all groups (after ACA) were greater than 150 mm Hg owing to 100% delivery of oxygen and increased ventilator rate (60 to 80 breaths per minute) during and after resuscitation. These results suggest that inhibition of PKCd can enhance eNOS levels responsible for vasodilation of cerebral arteries resulting in enhanced CBF 24 hours after ACA.
DISCUSSION
Previously, we showed that inhibition of PKCd via dV1-1 24 hours after ACA enhanced perfusion as compared with tat peptide pretreatment. 1 This led to subsequent studies aimed at defining how inhibition of PKCd is enhancing brain perfusion 24 hours after ACA. In this current study, we identified that PKCd targets directly or indirectly the NO machinery evidenced by enhanced L-arg and/ or SNP-induced CBF by TPLSM and LDF. In addition, inhibition of PKCd enhanced whole-blood nitrite concentration 24 hours after ACA suggesting that the attenuation via dV1-1-induced hypoperfusion 24 hours after ACA as shown previously 1 is most likely mediated by NO owing to the fact that nitrite is a major NO metabolite. 20 Furthermore, we show that there is a correlative elevation in eNOS levels.
It is without a doubt that SNP has been denoted as a NO donor causing vasodilation in cerebral as well as systemic arteries. Current dogma has led us to believe that this vasodilation can cause the possibility of increased CBF. [21] [22] [23] However, there are many reports that suggest otherwise. [24] [25] [26] Sodium nitroprussidemediated enhancement of CBF depends upon where and what type(s) of vasculature one is measuring from. Traditionally, studies involving ex vivo manipulation of cerebral or systemic vessel preparation has been used to study these types of phenomena utilizing pharmacological manipulations (i.e. in the presence or absence of SNP/NLA etc.) to determine vasodilation or vasoconstriction of cerebral vessels but it does not always directly correlate to enhanced CBF. In this study, we are not claiming vascular tonicity but only CBF perfusion in two techniques employed, the TPLSM of pial circulation and LDF. The objective (from TPLSM) or probe (from LDF) was placed 1 mm lateral to the bregma as published earlier. 1, 27 These two techniques are realtime CBF measurements to determine the effects of PKCd. We used L-arg, SNP, and NLA to define the relationship of PKCd and NOS machinery.
The therapeutic potential via the modulation of PKCd varies from vascular restenosis 28 to improvement of endothelial vascular dysfunction via inhibition of PKCd. 5 It is thought that the inhibition of PKCd (via dV1-1) can have beneficial effects against ischemia such as attenuation of hyperemia and hypoperfusion in models of global ischemia 1 and vascular protection against endothelial vascular dysfunction via modulation of eNOS. 5 In addition, degradation of PKCd during reperfusion improves physiologic outcome in the myocardial infarction 29 model altogether suggesting that ischemia causes activation/translocation of PKCd whereas inhibition or attenuation of PKCd can improve physiologic outcomes, as it relates to neuronal protection and/or revival of CBF. 1, 27 We and others have reported that inhibition of PKCd via dV1-1 can restore brain blood flow in global or regional ischemia, 1, 27, 30 but the mechanism of action remains controversial. In fact, Monti et al 5 suggest in models of cell culture that the effects of dV1-1 in endothelial cells can be complemented with the action of PKCe to modulate and stabilize eNOS preventing endothelial cell dysfunction. In addition, inhibition of PKCd can enrich endothelial cell survival under hypoxic conditions in human umbilical vein endothelial cells. 31 In coronary postcapillary venular endothelial cells, inhibition of PKCd with dV1-1 shifts PKCe to the cytoplasm and PKCe can then translocate to the membrane. Protein kinase C e activation promotes inhibition of eNOS resulting in decreased reactive oxygen species production via Akt phosphorylation. 5 This is contrary to our results. However, using a model of bovine aortic endothelial cells, Rask-Madsen and King, 32 suggested that PKCe can activate Akt and eNOS through the vascular endothelial growth factor pathway. 32 Together, these results from Monti et al 5 and Rask-Madsen and King 32 can provide a possible explanation of our results where inhibition of PKCd via dV1-1 can activate PKCe translocation causing enhanced eNOS expression. It is also important to note that although not without controversy, many of these studies were performed in cell culture systems using methods to mimic ischemia, such as serum deprivation. As cardiac arrest is a multi-faceted problem consisting of whole-body ischemia that compromises systemic blood parameters and cerebral, renal, and cardiac functions, consequent disruption of CBF, it is possible that our results can provide new additional insight into this problem. We initially used the TPLSM to detect changes in cortical CBF in the presence of L-arg and SNP. We observed L-arg-induced enhancement of CBF in pial circulation using TPLSM in the presence of PKCd inhibitor (dV1-1). As TPLSM technically measures RBC speed in pial circulation, we implemented LDF by observing regional CBF at the same location as TPLSM. Measuring RBC speed confirms that the effects observed via TPLSM were similar in the presence of NO substrates with the exception of SNP-induced enhancement of CBF in the presence of dV1-1 (Figures 1 and 2) . This discrepancy (SNP-induced relaxation between TPLSM and LDF methods) between the two methods may be attributed to the limitation of the TPLSM acquiring an image at B5-minute intervals to examine peak CBF per image, whereas LDF (probe placed 1 mm lateral to the bregma, similar to the acquisition of images via TPLSM) samples at a rate of 2 Hz to obtain the average of peak values during the drug application(s) (bolus intravenous injection of L-arg or SNP). We recognize that TPLSM is used to detect microvessel blood flow (p20 mm in diameter) whereas the use of LDF (using different technologies) detects overall CBF providing a more broad perspective (1 mm 3 ) as to the overall status of CBF in the presence of PKCd.
With the use of L-arg, NLA or SNP as a pharmacological method to detect the intricate involvement of NO in TPLSM and LDF experiments (Figures 1 and 2) , our data further support a major role of NO-mediated vasoactive modulation in the presence of PKCd. Our initial findings ( Figure 3 . Inhibition of protein kinase C (PKCd) enhanced endothelial-mediated nitric oxide synthase (eNOS) but not inducible NOS (iNOS) or neuronal NOS (nNOS) cortical protein expression 24 hours after asphyxial cardiac arrest (ACA). (A) Inhibition of PKCd (via dV1-1) pretreatment 30 minutes before ACA enhanced eNOS (dV1-1 þ ACA, 1.29 ± 0.12%) but not P(Ser1177)-eNOS protein expression 24 hours as compared with tat peptide (1.00 ± 0.08%) after ACA (B). Pretreatment with dV1-1 for 1 hour in the absence of ACA did not change eNOS protein expression (0.95 ± 0.01%) as compared with tat peptide þ ACA (B). Pretreatment with dV1-1 or tat peptide þ ACA did not change iNOS or nNOS protein expression (C-F). Parentheses inside the bar graphs represent the number of experiments performed. b-actin was used as an internal loading control in all blots (*Pp0.05).
in the presence or absence of dV1-1 suggest that whole-blood nitrite concentrations are elevated in the presence of dV1-1 24 hours after ACA as compared with sham, ACA, or tat peptide þ ACA. In a separate set of experiments, Western blot analyses (Figure 4 ) in whole cortical brain tissue suggest that the levels of eNOS but not phospho-eNOS were enhanced in the presence of ACA pretreated with dV1-1. Based on our overall evidence, it is suggestive that the nitrite (NO metabolite) from whole-blood could be derived from eNOS as correlated in our Western blot studies. However, we cannot rule out the possibility that the contributions of whole-blood nitrite can originate from iNOS, nNOS, or hemoglobin. 33 These results suggest that perhaps eNOS activation does not solely require phosphorylation in vivo unlike conventional NO activation pathways mediated by eNOS phosphorylation at serine 1177 or 1179. [34] [35] [36] Traditionally, phosphorylation sites at serine 1177/1179 36 causes eNOS activation while serine 495 is thought to be inhibitory. 37 The main hypothesis and the actual experimental design is addressing the inhibition of PKCd (via dV1-1) enhances eNOS after ACA as suggested in Figures 3 and 4 . We did not study S495 because when phosphorylated, inhibits eNOS. As the inhibition of PKCd enhances eNOS and theoretically decreases in phosphorylation, we focused on the activation site of eNOS.
Much of the current understanding regarding the mechanism of activation of NOS has been performed in intact cell cultures suggesting that perhaps there may be differential/additional factors (such as Ca 2 þ levels responsible for the modulation in various NOS systems) that mediate NOS activation. Others have suggested that the relationship between PKCd and eNOS activation may be tissue/cell specific. 5 Previously, others have shown that PKCd phosphorylates serine (1177/1179) resulting in eNOS activation in bovine aortic endothelial cells. 38 Attenuation of PKCd (via small interfering RNA) decreased NO production in fibroblasts. 39 In both of these studies, the authors used Rottlerin, which at the time was thought to be the only specific inhibitor of PKCd but others have shown that Rottlerin is not specific for PKCd. 40 Nonetheless, this leads to our novel findings, which suggest that inhibition of PKCd (via dV1-1) actually enhances whole-blood nitrite concentration (Figure 3 ) with eNOS-enhanced levels in the presence of ACA pretreated with dV1-1 (Figure 4 ). In addition, some investigators have suggested that enhanced P-eNOS in turn, inhibit PKCd expression in human umbilical vein endothelial cells induced with propofol 41 whereas Ramzy et al 42 suggested that decreased eNOS expression results in increased PKCd levels in human saphenous vein endothelial cells induced with endothelin-1. 42 Therefore, based on this information from Ramzy et al, 42 inhibition of PKCd will increase eNOS levels similar to our findings (Figure 4) .
In summary, we show that inhibition of PKCd via dV1-1 can enhance brain perfusion 24 hours after ACA. 1 This enhancement in CBF is most likely mediated via enhanced eNOS levels in the presence of PKC suppression. This is further evidenced by enhanced nitrite concentrations in whole-blood 24 hours after ACA in the presence of dV1-1. More studies are needed to define the physiologic role of eNOS in the context of cardiac arrest beyond activation via phosphorylation as well as defining the therapeutic value of modulation of PKCd (via dV1-1) against cerebral ischemia. ACA, asphyxial cardiac arrest; MABP, mean arterial blood pressure. Physiologic parameters such as pH, PCO 2 , PO 2, MABP, and blood glucose were measured to ensure consistency of the animals within and between groups. PO 2 for all groups (after ACA) were greater than 150 mm Hg owing to 100% delivery of oxygen and increased ventilator rate (60 breaths per minute to 80 breaths per minute) during and after resuscitation. Values are mean ± s.e.m.
